Estimating the future health burden of chronic hepatitis B and the impact of therapy in Spain

European Journal of Gastroenterology and Hepatology

Volumn 20, Issue 4, 2008, Pages 320-326

  Idris, Berlian I ^a,b   Brosa, Max ^c   Richardus, Jan H ^a   Esteban, Rafael ^c   Schalm, Solko W ^a   Buti, Maria ^c  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF INDONESIA   (Indonesia)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Antiviral resistance; Chronic hepatitis B; Future health burden; Lamivudine; Markov model; Mathematical simulation

Indexed keywords

HEPATITIS B(E) ANTIGEN; LAMIVUDINE;

ANTIVIRAL THERAPY; ARTICLE; COHORT ANALYSIS; COST CONTROL; DEATH; HEALTH CARE COST; HEPATITIS B; HISTOPATHOLOGY; HUMAN; MORBIDITY; MORTALITY; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; SIMULATION; SPAIN; VIRUS STRAIN;

ADULT; AGED; ANTIVIRAL AGENTS; COST OF ILLNESS; DRUG RESISTANCE, VIRAL; FEMALE; HEPATITIS B VACCINES; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; LIVER CIRRHOSIS; MALE; MARKOV CHAINS; MIDDLE AGED; MODELS, STATISTICAL; SPAIN;

EID: 40649105322     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e3282f340c8     Document Type: Article

References (32)

1. Wait S. Hepatitis B: revealing a silent killer; A workshop at the European Parliament. In: Wait S, editor, 2006.
2. Custer B, Sullivan SD, Hazlet TK, Iloeje U, Veenstra DL, Kowdley KV. Global epidemiology of hepatitis B virus. J Clin Gastroenterol 2004; 38 (10 Suppl):S158-S168.
3. Bonnani P, Pesavento G, Bechini A, Tiscione E, Mannelli F, Benucci C, Nostro AL. Impact of universal vaccination programmes on the epidemiology of hepatitis B: 10 years of experience in Italy. Vaccine 2003; 21:685-691.
4. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control. J Viral Hepat 2004; 11:97-107.
5. Fattovich G, Zagni I, Olivari N, Zanni S. Natural history of hepatitis B virus infection and disease. In: Buti M, Esteban R, editors. Hepatitis B. Barcelona: Permanyer; 2005.
6. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45:507-539.
7. Sola R, Cruz De Castro E, Hombrados M, Planas R, Coll S, Jardi R, et al. [Prevalence of hepatitis B and hepatitis C viruses in different counties of Catalonia, Spain: cross-sectional study]. Prevalencia de las hepatitis B y C en diversas comarcas de Cataluna: estudio transversal. Med Clin (Barc) 2002; 119:90-95.
8. Veldhuijzen IK, Smits LJ, van de Laar MJ. The importance of imported infections in maintaining hepatitis B in The Netherlands. Epidemiol Infect 2005; 133:113-119.
9. World Health Organization. Hepatitis B fact sheet no. 204. 2000.
10. World Health Organization. WHO vaccine preventable diseases monitoring system: 2004 global summary. Geneva: World Health Organization; 2004.
11. Mostert MC, Richardus JH, de Man RA. Referral of chronic hepatitis B patients from primary to specialist care: making a simple guideline work. J Hepatol 2004; 41:1026-1030.
12. Locarnini S, Hatzakis A, Heathcote J, Keeffe EB, Liang TJ, Mutimer D, et al. Management of antiviral resistance in patients with chronic hepatitis B. Antivir Ther 2004; 9:679-693.
13. Zoulim F. Detection of hepatitis B virus resistance to antivirals. J Clin Virol 2001; 21:243-253.
14. Kanwal F, Gralnek IM, Martin P, Dulai GS, Farid M, Spiegel BM. Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis. Ann Intern Med 2005; 142:821-831.
15. Spain National Statistics Institute. http://www.ine.es/ [Accessed in November 2006].
16. Buti M, Costa X, Valdes A, Cotrina M, Rodriguez Frias F, Jardi R, et al. [Study of hepatitis B virus replication and infection by other hepatitis viruses in patients with chronic hepatitis B virus infection]. Estudio de la replicacion del virus de la hepatitis B e infeccion por otros virus hepatotropos en pacientes con infeccion cronica por el virus B. Gastroenterol Hepatol 2002; 25:295-298.
17. Buti M, Esteban R. Hepatitis B. Barcelona: Permanyer Publications; 2005.
18. Petitti D. Meta-analysis, decision analysis, and cost-effectiveness analysis: methods for quantitative synthesis in medicine. New York: Oxford University Press; 2000.
19. Stein K, Rosenberg W, Wong J. Cost effectiveness of combination therapy for hepatitis C: a decision analytic model. Gut 2002; 50:253-258.
20. Council of Europe. International figures on organ, tissue & hematopoietic stem cell donation & transplantation activities (2004). Newsletter Transplant 2005; 10:26.
21. Otero-Ravina F, Rodriguez-Martinez M, Selles CF, Gutierrez MG, Blanco MD, de Rituerto ST, et al. Analysis of survival after liver transplantation in Galicia, Spain. Transplant Proc 2005; 37:3913-3915.
22. Lok AS, McMahon BJ. Chronic hepatitis B: update of recommendations. Hepatology 2004; 39:857-861.
23. de Franchis R, Hadengue A, Lau G, Lavanchy D, Lok A, et al.; EASL Jury. EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version). J Hepatol 2003; 39 (Suppl 1):S3-S25.
24. Kanwal F, Farid M, Martin P, Chen G, Gralnek IM, Dulai GS, et al. Treatment alternatives for hepatitis B cirrhosis: a cost-effectiveness analysis. Am J Gastroenterol 2006; 101:2076-2089.
25. Buti M, Casado MA, Fosbrook L, Wong JB, Esteban R. Cost-effectiveness of combination therapy for naive patients with chronic hepatitis C. J Hepatol 2000; 33:651-658.
26. Gold MR, Siegel JE, Russell LB, Weinstein MG. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996.
27. Fattovich G, Pantalena M, Zagni I, Realdi G, Schalm SW, Christensen E, et al. Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. Am J Gastroenterol 2002; 97:2886-2895.
28. Beck JR, Pauker SG. The Markov process in medical prognosis. Med Decis Making 1983; 3:419-458.
29. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993; 13:322-328.
30. Goldstein ST, Zhou F, Hadler SC, Bell BP, Mast EE, Margolis HS. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol 2005; 34:1329-1339.
31. Buti M, San Miguel R, Brosa M, Cabases JM, Medina M, Angel Casado M, et al. Estimating the impact of hepatitis C virus therapy on future liver-related morbidity, mortality and costs related to chronic hepatitis C. J Hepatol 2005; 42:639-645.
32. Wong JB, McQuillan GM, McHutchison JG, Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 2000; 90:1562-1569.